|Bid||19.08 x 1000|
|Ask||19.10 x 1000|
|Day's Range||18.90 - 19.89|
|52 Week Range||16.71 - 41.16|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.33|
WALTHAM, Mass., Oct. 12, 2018 -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 1, 2018. The.
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Radius Health, Inc. (RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced the latest 2019 Medicare Part D coverage for TYMLOS which increased to approximately 26.2 million lives or 64% of those enrolled in Medicare Part D plans in the U.S. Effective January 1, 2019, SilverScript Insurance Company (a CVS Caremark company), WellCare Health Plans, Inc., and Prime Therapeutics will become the latest Medicare Part D prescription drug plan (PDP) sponsors to cover TYMLOS® (abaloparatide) injection for their beneficiaries. Express Scripts, Inc., UnitedHealthcare (AARP), Kaiser Permanente, and EnvisionRx, among others, have decided to continue Medicare Part D coverage of TYMLOS through 2019.
WALTHAM, Mass., Sept. 28, 2018-- Radius Health, Inc. announced today that Jesper Høiland, President and CEO and Charles Morris, Chief Medical Officer of the Company will present a corporate update at the ...
Radius Health, Inc. (RDUS), a science-driven fully integrated biopharmaceutical company committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will present four posters, including new analyses from the Phase 3 ACTIVExtend trial of abaloparatide injection, at the upcoming American Society for Bone and Mineral Research (ASBMR) 2018 Annual Meeting, which will take place in Montreal. “As a company committed to advancing the understanding and management of osteoporosis, we are pleased to be sharing abaloparatide clinical data with physicians at this important medical meeting,” said Bruce Mitlak, M.D., Radius Health’s Vice President of Clinical Development.
WALTHAM, Mass., Sept. 11, 2018-- Radius Health, Inc. announced today that Jesper Høiland, President and CEO, and Pepe Carmona, Chief Financial Officer of the Company, will present a corporate update at ...
WALTHAM, Mass., Sept. 06, 2018-- Radius Health, Inc. today announced that the Company’ s Board of Directors granted Dr. Charles Morris, in connection with his appointment as the Company’ s Chief Medical ...
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius Health, Inc. ("Radius" or the "Company") (RDUS) today announced the appointment of Dr. Charles Morris as Chief Medical Officer. Dr. Morris will oversee and lead all clinical development, regulatory and medical affairs strategies and activities of the Company. "I am delighted to welcome Charlie as our Chief Medical Officer at this key stage of our clinical pipeline progress and expansion to oncology,” said Jesper Høiland, President and Chief Executive Officer of Radius.
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the appointment of Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations, effectively immediately. Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, commented, “David possesses a wealth of knowledge and expertise in drug development, clinical and commercial manufacturing, and supply chain management which will be instrumental in the success of our clinical programs, BXCL501 and BXCL701, as well as setting the stage for our commercial operations.
Radius Health (RDUS) delivered earnings and revenue surprises of 25.00% and 8.58%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of $1.52. Losses, adjusted for non-recurring costs and stock option expense, were 99 cents per share. The results surpassed ...
Second quarter 2018 TYMLOS sales increase to $22.6 million, a 56% increase over the first quarter of 2018. TYMLOS’ share in the U.S. anabolic osteoporosis market increased to an average of 19% in the second ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Radius Health Inc (NASDAQ: RDUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:00:00 AM Eastern Time. ...
Investors will focus on lead drug Tymlos' uptake and an update on Radius Health's (RDUS) marketing application for the drug in Europe, when it reports second-quarter results on Aug 7.
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ladder ...
LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. Losses were broad based as seven out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Sarepta Therapeutics Inc. (NASDAQ: SRPT).
Radius Health, Inc. (RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced that after an oral explanation following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has communicated a negative trend vote for the Company’s marketing authorization application (MAA) for abaloparatide-SC for the treatment of osteoporosis in postmenopausal women at increased risk for fracture. A negative trend vote means that it is likely that the CHMP will maintain its negative opinion for the MAA at its formal final vote, which it has indicated will occur prior to the end of its meeting this week.